Registry for tracking myasthenia gravis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Vitaccess Real MG Registry is an observational patient registry aimed at collecting longitudinal data on myasthenia gravis (MG) patients, focusing on their treatment, symptoms, daily activities, and quality of life over a 10-year period. Approximately 600 patients will be recruited from the US and Europe, utilizing both traditional clinical site recruitment and community neurologist outreach in the US. Data will be gathered through a digital platform, allowing for patient-reported outcomes and clinical data integration from medical records. This comprehensive approach aims to enhance understanding of MG's impact on patients' lives.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult (age ≥18 years) with a clinically-confirmed diagnosis of myasthenia gravis (MG).
* Resident in one of the scope countries.
* Access to a smartphone/tablet/computer/laptop
* Willing and able to provide informed consent in their local language to take part in the study.

Exclusion Criteria:

* Participation in a clinical trial at the time of study enrolment.

Where it's running

• UCI Health
  Orange, California, United States Recruiting
• HSHS St. Elizabeth's Hospital
  O'Fallon, Illinois, United States Recruiting
• UK HealthCare - University of Kentucky
  Lexington, Kentucky, United States Recruiting
• Neurology Associates of South Jersey
  Lumberton, New Jersey, United States Recruiting
• Medical University South Carolina
  Charleston, South Carolina, United States Recruiting
• University of Texas Health Science Center at Houston
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Mark JW Larkin, PhD — Vitaccess Ltd
• Study coordinator: Mark JW Larkin, PhD
• Email: mark.larkin@vitaccess.com
• Phone: +44 1865818983

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MG patient registry to track long-term experiences and treatment patterns

  This registry collects information from adults with myasthenia gravis to see how symptoms and quality of life change over time and how treatments relate to those changes.

  Recruiting Autoimmune Neurology Alliance · Framingham, Massachusetts · NCT07761026

• Ublituximab maintenance after efgartigimod response in myasthenia gravis

  This study tests whether giving ublituximab as maintenance after a positive response to efgartigimod helps adults with myasthenia gravis.

  Recruiting at 7 sites Phase 2 TG Therapeutics, Inc. · Colorado Springs, Colorado and 6 other locations · NCT07673744

• Pregnant Women with Neuroimmune Diseases: A long-term follow-up study

  This study follows women with neuroimmune diseases and healthy controls through pregnancy and up to ten years to see how pregnancy affects disease activity and outcomes for both mother and baby.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT07653984

• Early ravulizumab for adults with myasthenic crisis in the ICU

  This project will test whether giving ravulizumab early to adults with AChR-positive generalized myasthenia gravis who are in the ICU for a myasthenic crisis helps speed recovery.

  Recruiting at 5 sites Centre Hospitalier Universitaire de Nice · Nice, Alpes-maritimes and 7 other locations · NCT07411963

• KITE-363 treatment for relapsed or refractory autoimmune neurologic diseases

  This study will test whether KITE-363 is safe and can help people with relapsed or treatment-resistant autoimmune neurologic diseases such as MS, CIDP, and myasthenia gravis.

  Recruiting at 10 sites Phase 1 Gilead Sciences · Newport Beach, California and 9 other locations · NCT07304154

• ADAPT Forward master protocol testing multiple regimens for generalized myasthenia gravis

  This platform tests several drug regimens, including efgartigimod IV and empasiprubart IV, in adults with generalized myasthenia gravis to find safer and more effective treatment combinations.

  Recruiting at 37 sites argenx · Carlsbad, California and 36 other locations · NCT07294170

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.